Gustavo Citera

Gustavo Citera

Auto-generated profile, based on publicly available information

Gustavo Citera

Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
ABAndra Rodica Balanescu
Andra Rodica Balanescu
GCGustavo Citera
Gustavo Citera
VPVirginia Pascual-Ramos
Virginia Pascual-Ramos
DBDeepak L Bhatt
Deepak L Bhatt
CCCarol A Connell
Carol A Connell
HSHendrik Schulze-Koops
Hendrik Schulze-Koops
Objectives To characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance. Methods In this open-label, randomised controlled trial, patients with RA aged≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times per day or a tumour necrosis factor inhibitor (TNFi). Incidence rates (IRs; patients with first events/100 patient-years) and hazard ratios (HRs) were calculated for infections, overall and by age (50–5 mg two times per day) versus TNFi. For SIEs, HR (95% CI) for tofacitinib 5 and 10 mg two times per day versus TNFi, respectively, were 1.17 (0.92 to 1.50) and 1.48 (1.17 to 1.87). Increased IRs/HRs for all infections and SIEs with tofacitinib 10 mg two times per day versus TNFi were more pronounced in patients aged≥65 vs 50–<65 years. SIE probability increased from month 18 and before month 6 with tofacitinib 5 and 10 mg two times per day versus TNFi, respectively. NSI probability increased before month 6 with both tofacitinib doses versus TNFi. Across treatments, the most predictive risk factors for SIEs were increasing age, baseline opioid use, history of chronic lung disease and time-dependent oral corticosteroid use, and, for NSIs, female sex, history of chronic lung disease/infections, past smoking and time-dependent Disease Activity Score in 28 joints, C-reactive protein. Conclusions Infections were higher with tofacitinib versus TNFi. Findings may inform future treatment decisions. Trial registration number NCT02092467.

6 October 2023 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
WBWilson Bautista-Molano
Wilson Bautista-Molano
DFDaniel G. Fernández-Ávila
Daniel G. Fernández-Ávila
MBMaría Lorena Brance
María Lorena Brance
MPMaría Gabriela Ávila Pedretti
María Gabriela Ávila Pedretti
RBRuben Burgos-Vargas
Ruben Burgos-Vargas
ESEnrique R. R. Soriano
Enrique R. R. Soriano

21 March 2013 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
PAPablo Arturi
Pablo Arturi
ESEmilce Edith Schneeberger
Emilce Edith Schneeberger
FSFernando Sommerfleck
Fernando Sommerfleck
EBEmilio Buschiazzo
Emilio Buschiazzo
CLCésar Ledesma
César Ledesma
GCGustavo Citera
Gustavo Citera

8 January 2021 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
GCGustavo Citera
Gustavo Citera
WBWilson Bautista-Molano
Wilson Bautista-Molano
IPIngris Peláez-Ballestas
Ingris Peláez-Ballestas
VAValderilio F. Azevedo
Valderilio F. Azevedo
RPRisto A. Perich
Risto A. Perich
CBCecilia E. Borlenghi
Cecilia E. Borlenghi
Large epidemiologic and clinical estimates of spondyloarthritis (SpA) in Latin America are not available. In this narrative review, our goal was to descriptively summarize the prevalence and features of SpA in Latin America, based on available small studies. A review of peer-reviewed literature identified 41 relevant publications. Of these, 11 (mostly based on Mexican data) estimated the prevalence of SpA and its subtypes, which varied from 0.28 to 0.9% (SpA), 0.02 to 0.8% (ankylosing spondylitis), 0.2 to 0.9% (axial SpA), and 0.004 to 0.08% (psoriatic arthritis). Demographic and/or clinical characteristics were reported in 31 of the 41 publications, deriving data from 3 multinational studies, as well as individual studies from Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, Peru, Uruguay, and Venezuela. Data relating to treatment, disease manifestations (articular and extra-articular), and comorbidities were summarized across the countries. Available data suggest that there is a variability in prevalence, manifestations, and comorbidities of SpA across Latin America. Basic epidemiologic and clinical data are required from several countries not currently represented. Data relating to current treatment approaches, patient outcomes, and socioeconomic impact within this large geographic region are also needed.

20 August 2020 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Open access
GCGustavo Citera
Gustavo Citera
EMEduardo Mysler
Eduardo Mysler
HMHugo Madariaga
Hugo Madariaga
MCMario H. Md Cardiel
Mario H. Md Cardiel
OCOswaldo Castañeda
Oswaldo Castañeda
DLDario Ponce de Leon
Dario Ponce de Leon
Background/Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Interstitial lung disease (ILD) is an extra-articular manifestation of RA. We investigated incidence rates of ILD in patients with RA, receiving tofacitinib 5 or 10 mg twice daily, and identified potential risk factors for ILD. Methods: This post hoc analysis comprised a pooled analysis of patients receiving tofacitinib 5 or 10 mg twice daily or placebo from 2 phase (P)1, 10 P2, 6 P3, 1 P3b/4, and 2 long-term extension studies. Interstitial lung disease events were adjudicated as “probable” (supportive clinical evidence) or “possible” (no supportive clinical evidence) compatible adverse events. Incidence rates (patients with events per 100 patient-years) were calculated for ILD events. Results: Of 7061 patients (patient-years of exposure = 23,393.7), 42 (0.6%) had an ILD event; median time to ILD event was 1144 days. Incidence rates for ILD with both tofacitinib doses were 0.18 per 100 patient-years. Incidence rates generally remained stable over time. There were 17 of 42 serious adverse events (40.5%) of ILD; for all ILD events (serious and nonserious), 35 of 42 events (83.3%) were mild to moderate in severity. A multivariable Cox regression analysis identified age 65 years or older (hazard ratio 2.43 [95% confidence interval, 1.13–5.21]), current smokers (2.89 [1.33–6.26]), and Disease Activity Score in 28 joints–erythrocyte sedimentation rate score (1.30 [1.04–1.61]) as significant risk factors for ILD events. Conclusions: Across P1/2/3/4/long-term extension studies, incidence rates for ILD events were 0.18 following tofacitinib treatment, and ILD events were associated with known risk factors for ILD in RA.

24 July 2020 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
CICarolina A. Isnardi
Carolina A. Isnardi
DCDafne Capelusnik
Dafne Capelusnik
ESEmilce Edith Schneeberger
Emilce Edith Schneeberger
MBMarcela Bazzarelli
Marcela Bazzarelli
LBLaura Ot Berloco
Laura Ot Berloco
GCGustavo Citera
Gustavo Citera
Objective: The aim of this study was to determine the prevalence of depression among rheumatoid arthritis (RA) Argentinean patients and its association with sociodemographic and clinical factors. Methods: We performed a cross-sectional study of consecutive adults with RA. Sociodemographic data, comorbidities, RA disease activity, and current treatment were assessed. The following instruments were used to evaluate quality of life (EQ-5D-3 L [EURO Quality 5-dimension 3 lines], QOL-RA [Quality of Life–Rheumatoid Arthritis]), functional capacity (HAQ-A [Health Assessment Questionnaire–Argentinean version]), and depression (PHQ-9 [Patient Health Questionnaire 9]; scores 5–9: mild, 10–14: moderate, 15–19: moderate-severe, and ≥20: severe depression, a cutoff value ≥10 is diagnostic of major depression). Results: Two hundred fifty-eight patients were included, with a median disease duration of 9 years (interquartile range, 3.6–16.7 years). The m PHQ-9 score was 6 (interquartile range, 2–12.3 years). The prevalence of major depression was 33.8%. The frequency of mild, moderate, moderate/severe, and severe depression was 66 (25.6%), 42 (16.3%), 27 (10.5%), and 18 (7%), respectively. Patients with major depression had worse functional capacity (HAQ-A: mean ± SD, 1.6 ± 0.8 vs. 0.7 ± 0.7; p < 0.0001), poorer quality of life (QOL-RA: mean ± SD, 5.4 ± 1.8 vs. 7.3 ± 1.6; p < 0.0001), greater pain (visual analog scale: mean ± SD, 56.2 ± 27.5 mm vs. 33.4 ± 25.7 mm; p < 0.0001), higher disease activity (Disease Activity Score in 28 joints: mean ± SD, 4.3 ± 1.4 vs. 3.3 ± 1.3; p < 0.0001), higher frequency of comorbidities (67% vs. 33%; p = 0.017), and lower frequency of physical activity (22% vs. 35%; p = 0.032). In the multivariate analysis, patients with moderate and severe depression had worse functional capacity (odds ratio, 2.1; 95% confidence interval, 1.6–4.3; p < 0.0001) and quality of life (odds ratio, 0.7; 95% confidence interval, 0.5–0.8; p < 0.0001), independently of disease activity. Conclusions: A third of RA patients in this Argentinean cohort had major depression. In those patients, depression was associated with worst functional capacity and quality of life.